metaPreg - Desvenlafaxine during pregnancy

Desvenlafaxine updated on 10-20-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.75 [0.14, 4.09]	-	1 study	30,630	6	not evaluable	ROB	-
Congenital heart defects	-	-	0 study					-
Major congenital malformations	0.75 [0.14, 4.09]	-	1 study	30,630	6	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	0.81 [0.18, 3.64]	-	1 study	63	16	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Jaundice / Icterus	1.26 [0.35, 4.54]	-	1 study	66	16	not evaluable	ROB	-
Low Apgar score (< 7) (at 5 min)	1.64 [0.45, 5.97]	-	1 study	53	16	not evaluable	ROB	-
Neonatal medical care	0.98 [0.26, 3.72]	-	1 study	94	16	not evaluable	ROB	-
Neonatal tachypnea	0.34 [0.02, 5.75]	-	1 study	35	16	not evaluable	ROB	-
Persistent pulmonary hypertension	26.16 [0.50, 1362.35]	-	1 study		16	not evaluable	ROB	-
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	1.13 [0.13, 9.68]	-	1 study	20	16	not evaluable	ROB	-
Hide endpoints reported in only one study ...